Becenun
Becenun Brand names, Becenun Analogs
Becenun Brand Names Mixture
- No information avaliable
Becenun Chemical_Formula
C5H9Cl2N3O2
Becenun RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Becenun fda sheet
Becenun msds (material safety sheet)
Becenun Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Becenun Molecular Weight
214.049 g/mol
Becenun Melting Point
31 oC
Becenun H2O Solubility
< 0.1 g/100 mL at 18 °C
Becenun State
Solid
Becenun LogP
1.256
Becenun Dosage Forms
Powder for solution; Wafer
Becenun Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Becenun Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Becenun Absorption
5 to 28% bioavailability
Becenun side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Becenun Patient Information
No information avaliable
Becenun Organisms Affected
Humans and other mammals
